Nicolas Guisot

This inventor holds 11 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Loxo Oncology, Inc.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicolas Guisot. Retrieved from https://idiyas.com/inventor/nicolas-guisot

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 3)

% Patents Active = 90.9

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 7(Granted Patents)

Company Filing History:

11 out of 35

Loxo Oncology, Inc.

patents

Years Active: 2019-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12220401 - Compounds useful as kinase inhibitors (2025-02-11),

2. 11826351 - Compounds useful as kinase inhibitors (2023-11-28),

3. 11471441 - Compounds useful as kinase inhibitors (2022-10-18),

4. 10918622 - Compounds useful as kinase inhibitors (2021-02-16),

5. 10695323 - Compounds useful as kinase inhibitors (2020-06-30),

6. 10611766 - Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer (2020-04-07),

7. 10538524 - Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase (2020-01-21),

8. 10464905 - Compounds useful as kinase inhibitors (2019-11-05),

9. 10399990 - Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer (2019-09-03),

10. 10399989 - Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer (2019-09-03),

11. 10342780 - Compounds useful as kinase inhibitors (2019-07-09),

Title: Innovations by Nicolas Guisot

Introduction

Nicolas Guisot is a prominent inventor based in Cheshire, GB. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that serve as kinase inhibitors. With a total of 11 patents to his name, Guisot's work has the potential to impact the treatment of various medical conditions.

Latest Patents

One of Guisot's latest patents focuses on novel compounds that are useful as inhibitors of Bruton's tyrosine kinase (BTK). This invention is particularly relevant for treating conditions such as cancer, lymphoma, leukemia, and immunological diseases. The compounds developed by Guisot are designed to inhibit BTK, which plays a crucial role in the signaling pathways of these diseases.

Career Highlights

Guisot is currently associated with Loxo Oncology, Inc., where he continues to innovate in the field of kinase inhibitors. His expertise and dedication to research have positioned him as a key figure in the biotechnology sector.

Collaborations

Guisot collaborates with various professionals in his field, including his coworker Mathew Calder. Their combined efforts contribute to the advancement of medical treatments and the development of new therapeutic compounds.

Conclusion

Nicolas Guisot's work in developing kinase inhibitors showcases his commitment to advancing medical science. His innovative patents have the potential to significantly improve treatment options for patients suffering from serious health conditions.

Profile summary based on public USPTO records.